Exploring Second Line Systemic Therapy In Hcc
Let's dive into the details surrounding Second Line Systemic Therapy In Hcc.
- A review of a phase 3 trial on cabozantinib as well as the use of regorafenib and ramucirumab as seen in the RESORCE and ...
- Julien Edeline, MD, PhD, Centre Eugene Marquis, Rennes, France, discusses real-world data from the CHIEF cohort, which ...
- Secondary systemic treatment
- Ghassan K. Abou-Alfa, MD; Mark H. O'Hara, MD; Mark W. Karwal, MD; and A. Ruth He, MD, PhD, highlight the accelerated ...
- Panelists Ghassan K. Abou-Alfa, MD; Amit G. Singal, MD; and Richard Finn, MD, outline patient and disease factors to consider ...
In-Depth Information on Second Line Systemic Therapy In Hcc
Ghassan K. Abou-Alfa, MD, discusses the rationale for using regorafenib in a patient with metastatic Panelists Richard S. Finn, MD; Jordi Bruix, MD; and Richard H. Marshall, MD, review the results from the RESORCE clinical trial ... This video is part of the HMP Education content archive and may include previously accredited educational material. While this ... Richard S. Finn, MD, comments on the use of liver-directed
Data from the CELESTIAL trial looking at the tyrosine kinase inhibitor cabozantinib for patients with relapsed or refractory ...
That wraps up our extensive overview of Second Line Systemic Therapy In Hcc.